Trends and Outcomes in Sepsis Hospitalizations With and Without Atrial Fibrillation: A Nationwide Inpatient Analysis.


Journal

Critical care medicine
ISSN: 1530-0293
Titre abrégé: Crit Care Med
Pays: United States
ID NLM: 0355501

Informations de publication

Date de publication:
08 2019
Historique:
pubmed: 17 5 2019
medline: 17 4 2020
entrez: 17 5 2019
Statut: ppublish

Résumé

Atrial fibrillation is frequently seen in sepsis-related hospitalizations. However, large-scale contemporary data from the United States comparing outcomes among sepsis-related hospitalizations with versus without atrial fibrillation are limited. The aim of our study was to assess the frequency of atrial fibrillation and its impact on outcomes of sepsis-related hospitalizations. Retrospective cohort study. The National Inpatient Sample databases (2010-2014). Primary discharge diagnosis of sepsis with and without atrial fibrillation were identified using prior validated International Classification of Diseases, 9th Edition, Clinical Modification codes. None. Overall, 5,808,166 hospitalizations with the primary diagnosis of sepsis, of which 19.4% (1,126,433) were associated with atrial fibrillation. The sepsis-atrial fibrillation cohort consisted of older (median [interquartile range] age of 79 yr [70-86 yr] vs 67 yr [53-79 yr]; p < 0.001) white (80.9% vs 68.8%; p < 0.001) male (51.1% vs 47.5%; p < 0.001) patients with an extended length of stay (median [interquartile range] 6 d [4-11 d] vs 5 d [3-9 d]; p < 0.001) and higher hospitalization charges (median [interquartile range] $44,765 [$23,234-$88,657] vs $35,737 [$18,767-$72,220]; p < 0.001) as compared with the nonatrial fibrillation cohort. The all-cause mortality rate in the sepsis-atrial fibrillation cohort was significantly higher (18.4% and 11.9%; p = 0.001) as compared with those without atrial fibrillation. Although all-cause mortality (20.4% vs 16.6%) and length of stay (median [interquartile range] 7 d [4-11 d] vs 6 d [4-10 d]) decreased between 2010 and 2014, hospitalization charges increased (median [interquartile range] $41,783 [$21,430-$84,465] vs $46,251 [$24,157-$89,995]) in the sepsis-atrial fibrillation cohort. The greatest predictors of mortality in the atrial fibrillation-sepsis cohort were African American race, female gender, advanced age, and the presence of medical comorbidities. The presence of atrial fibrillation among sepsis-related hospitalizations is a marker of poor prognosis and increased mortality. Although we observed rising trends in sepsis and sepsis-atrial fibrillation-related hospitalizations during the study period, the rate and odds of mortality progressively decreased.

Identifiants

pubmed: 31094740
doi: 10.1097/CCM.0000000000003806
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e630-e638

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Auteurs

Rupak Desai (R)

Division of Cardiology, Atlanta Veterans Affairs Medical Center, Decatur, GA.

Bishoy Hanna (B)

Division of Cardiology, Morehouse School of Medicine, Atlanta, GA.

Sandeep Singh (S)

Division of Clinical Epidemiology, Biostatistics and Bioinformatics, Academic Medical Center, Amsterdam, The Netherlands.

Ahmed Omar (A)

Department of Internal Medicine, Morehouse School of Medicine, Atlanta, GA.

Abhishek Deshmukh (A)

Division of Cardiology, Mayo Clinic, Rochester, MN.

Gautam Kumar (G)

Division of Cardiology, Atlanta Veterans Affairs Medical Center, Decatur, GA.
Division of Cardiology, Emory University School of Medicine, Atlanta, GA.

Marilyn G Foreman (MG)

Division of Pulmonary and Critical Care Medicine, Morehouse School of Medicine, Atlanta, GA.

Rajesh Sachdeva (R)

Division of Cardiology, Atlanta Veterans Affairs Medical Center, Decatur, GA.
Division of Cardiology, Morehouse School of Medicine, Atlanta, GA.
Division of Cardiology, Emory University School of Medicine, Atlanta, GA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH